Markers of Natural Killer Cell Exhaustion in HIV/HCV Coinfection and Their Dynamics After HCV Clearance Mediated by Direct-Acting Antivirals

被引:0
作者
Osegueda, Ariel [1 ,2 ]
Polo, Maria Laura [1 ,2 ]
Baquero, Lucia [1 ,3 ]
Urioste, Alejandra [1 ,2 ]
Ghiglione, Yanina [1 ,2 ]
Paz, Silvia [4 ]
Poblete, Gabriela [4 ]
Gonzalez Polo, Virginia [1 ,2 ]
Turk, Gabriela [1 ,3 ]
Quiroga, Maria Florencia [1 ,3 ]
Laufer, Natalia [1 ,3 ,5 ]
机构
[1] Univ Buenos Aires, Inst Invest Biomed Retrovirus & SIDA INBIRS, CONICET, Buenos Aires, Argentina
[2] Univ Buenos Aires, Fac Med, Buenos Aires, Argentina
[3] Univ Buenos Aires, Dept Microbiol Parasitol & Inmunol, Fac Med, Buenos Aires, Argentina
[4] Hosp Francisco Javier Muniz, Buenos Aires, DF, Argentina
[5] Univ Buenos Aires, Fac Med, Inst Invest Biomed Retrovirus & SIDA, Paraguay 2155 Piso 11,C1121ABG, Buenos Aires, Argentina
来源
OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 12期
关键词
direct-acting antivirals; HIV/HCV coinfection; immunology; liver fibrosis; NK cell exhaustion; FIBROSIS; MORTALITY;
D O I
10.1093/ofid/ofad591
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Liver fibrosis is a leading cause of morbimortality in people with HIV/hepatitis C virus (HCV). Natural killer (NK) cells are linked with amelioration of liver fibrosis; however, NK cells from individuals coinfected with HIV/HCV with cirrhosis display impaired functionality and high PD-1 expression. Here, we aimed to study PD-1, TIGIT, and Tim3 as potential exhaustion markers in NK cells from persons coinfected with HIV/HCV with mild and advanced liver fibrosis. We also evaluated the role of PD-1 expression on NK cells after HCV clearance by direct-acting antivirals (DAAs).Methods Peripheral blood mononuclear cells were isolated from individuals coinfected with HIV/HCV (N = 54; METAVIR F0/F1, n = 27; F4, evaluated by transient elastography, n = 27). In 26 participants, samples were collected before, at the end of, and 12 months after successful DAA treatment. The frequency, immunophenotype (PD-1, TIGIT, and Tim3 expression), and degranulation capacity (CD107a assay) of NK cells were determined by flow cytometry.Results Unlike PD-1, Tim3 and TIGIT were comparably expressed between persons with mild and advanced fibrosis. Degranulation capacity was diminished in NK/TIGIT+ cells in both fibrosis stages, while NK/PD-1+ cells showed a lower CD107a expression in cirrhotic cases. Twelve months after DAA treatment, those with advanced fibrosis showed an improved NK cell frequency and reduced NK/PD-1+ cell frequency but no changes in CD107a expression. In individuals with mild fibrosis, neither PD-1 nor NK cell frequency was modified, although the percentage of NK/CD107a+ cells was improved at 12 months posttreatment.Conclusions Although DAA improved exhaustion and frequency of NK cells in cirrhotic cases, functionality was reverted only in mild liver fibrosis, remarking the importance of an early DAA treatment. PD-1 and TIGIT are associated with impaired natural killer (NK) cell functionality in individuals coinfected with HIV/HCV. NK cell degranulation capacity improved in persons with mild fibrosis after direct-acting antiviral treatment. In cases of cirrhosis, although frequency of NK cells was restored, loss of functionality was not.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine
    Malik, Farihah
    Malyuta, Ruslan
    Volokha, Alla
    Bailey, Heather
    Collins, Intira Jeannie
    Thorne, Claire
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (05) : 417 - 419
  • [32] Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy
    Milazzo, L.
    Lai, A.
    Calvi, E.
    Ronzi, P.
    Micheli, V.
    Binda, F.
    Ridolfo, A. L.
    Gervasoni, C.
    Galli, M.
    Antinori, S.
    Sollima, S.
    HIV MEDICINE, 2017, 18 (04) : 284 - 291
  • [33] Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients
    Carrasco, Itziar
    Sainz, Talia
    Antoinette Frick, Marie
    Jimenez de Ory, Santiago
    Fortuny, Claudia
    Burgos, Joaquin
    Montero, Marta
    Gavilan, Cesar
    Dolores Falcon, Maria
    Antonio Couceiro, Jose
    Ignacio Bernardino, Jose
    Bisbal, Otilia
    Guerrero, Carmelo
    Teresa Aldamiz-Echevarria, Maria
    Berenguer, Juan
    Luisa Navarro, Maria
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 955 - 958
  • [34] Treatment rate for HCV in the direct-acting antivirals era in HIV co-infected patients: data from an Italian cohort
    Cuomo, Gianluca
    Puzzolante, Cinzia
    Lazzaretti, Claudia
    Guaraldi, Giovanni
    Borghi, Vanni
    Mussini, Cristina
    MINERVA MEDICA, 2018, 109 (03) : 203 - 210
  • [35] Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy
    Pontali, Emanuele
    Fiore, Vito
    Ialungo, Anna Maria
    Ranieri, Roberto
    Mollaretti, Oscar
    Barbarini, Giorgio
    Marri, Daniele
    Prestileo, Tullio
    Dell'Isola, Serena
    Rastrelli, Elena
    Leo, Guido
    Starnini, Giulio
    Babudieri, Sergio
    Madeddu, Giordano
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 59 : 50 - 53
  • [36] Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-Acting Antivirals
    Yuval A. Patel
    Andrew J. Muir
    Current Hepatology Reports, 2016, 15 (4) : 285 - 290
  • [37] Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
    Pinero, Federico
    Mendizabal, Manuel
    Ridruejo, Ezequiel
    Wolff, Fernando Herz
    Ameigeiras, Beatriz
    Anders, Margarita
    Schinoni, Maria Isabel
    Reggiardo, Virginia
    Palazzo, Ana
    Videla, Maria
    Alonso, Cristina
    Santos, Luisa
    Varon, Adriana
    Figueroa, Sebastian
    Vistarini, Cecilia
    Adrover, Raul
    Fernandez, Nora
    Perez, Daniela
    Tanno, Federico
    Hernandez, Nelia
    Sixto, Marcela
    Borzi, Silvia
    Bruno, Andres
    Cocozzella, Daniel
    Soza, Alejandro
    Descalzi, Valeria
    Estepo, Claudio
    Zerega, Alina
    de Araujo, Alexandre
    Cheinquer, Hugo
    Silva, Marcelo
    Barreyro, F.
    Billordo, A.
    Caballini, P.
    Carbonetti, R.
    Ceballos, S.
    Deltrozzo, V
    Gadea, C.
    Garraztazul, P.
    Garrocho, C.
    Manero, E.
    Mendoza, C.
    Mengarelli, S.
    Moreno, V
    Peralta, M.
    Ratusnu, N.
    Romero, G.
    Ruf, A.
    Tanno, M.
    Tanno, F.
    LIVER INTERNATIONAL, 2019, 39 (06) : 1033 - 1043
  • [38] Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
    Conti, Fabio
    Buonfiglioli, Federica
    Scuteri, Alessandra
    Crespi, Cristina
    Bolondi, Luigi
    Caraceni, Paolo
    Foschi, Francesco Giuseppe
    Lenzi, Marco
    Mazzella, Giuseppe
    Verucchi, Gabriella
    Andreone, Pietro
    Brillanti, Stefano
    JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 727 - 733
  • [39] miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV?
    Du, Lingyao
    Tang, Hong
    FUTURE VIROLOGY, 2016, 11 (12) : 753 - 756
  • [40] Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals
    Campello, Elena
    Radu, Claudia M.
    Zanetto, Alberto
    Bulato, Cristiana
    Shalaby, Sarah
    Spiezia, Luca
    Franceschet, Enrica
    Burra, Patrizia
    Russo, Francesco P.
    Simioni, Paolo
    LIVER INTERNATIONAL, 2020, 40 (04) : 913 - 920